NCT01646125 - An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2012

Primary Completion Date

November 4, 2015

Study Completion Date

November 4, 2015

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

AUY922

AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.

DRUG

Docetaxel

Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity

DRUG

Pemetrexed

Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity

Trial Locations (27)

407

Novartis Investigative Site, Taichung

5021

Novartis Investigative Site, Bergen

10043

Novartis Investigative Site, Orbassano

10048

Novartis Investigative Site, Taipei

13915

Novartis Investigative Site, Marseille

20133

Novartis Investigative Site, Milan

20850

Maryland Oncology Hematology, P.A. SC, Rockville

20900

Novartis Investigative Site, Monza

28034

Novartis Investigative Site, Madrid

33305

Novartis Investigative Site, Kuei-Shan Chiang

43100

Novartis Investigative Site, Parma

90048

Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles

94000

Novartis Investigative Site, Créteil

94805

Novartis Investigative Site, Villejuif

53792-6164

University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5, Madison

Unknown

Novartis Investigative Site, Hong Kong

135 8550

Novartis Investigative Site, Koto Ku

1081 HV

Novartis Investigative Site, Amsterdam

9713 GZ

Novartis Investigative Site, Groningen

NO-0424

Novartis Investigative Site, Oslo

80 952

Novartis Investigative Site, Gdansk

05505

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

06591

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

LE1 5WW

Novartis Investigative Site, Leicester